LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

LLY

787.08

-1.04%↓

JNJ

153.17

+0.49%↑

ABBV

186.31

-0.36%↓

NVO

68.75

+1.9%↑

UNH

309.27

+1.9%↑

Search

Pacira Pharmaceuticals Inc-DE

Avatud

SektorTervishoid

23.75 0.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.21

Max

23.84

Põhinäitajad

By Trading Economics

Sissetulek

-11M

4.8M

Müük

-18M

169M

P/E

Sektori keskmine

11.23

50.291

Aktsiakasum

0.62

Kasumimarginaal

2.849

Töötajad

788

EBITDA

-17M

34M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+73.98% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-88M

1.1B

Eelmine avamishind

23.24

Eelmine sulgemishind

23.75

Uudiste sentiment

By Acuity

50%

50%

154 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2025, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2. juuli 2024, 16:22 UTC

Suurimad hinnamuutused turgudel

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Võrdlus sarnastega

Hinnamuutus

Pacira Pharmaceuticals Inc-DE Prognoos

Hinnasiht

By TipRanks

73.98% tõus

12 kuu keskmine prognoos

Keskmine 41.25 USD  73.98%

Kõrge 65 USD

Madal 26 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Pacira Pharmaceuticals Inc-DE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

3

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

24.83 / 26.38Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

154 / 380 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.